Related Experiment Video
Updated: Aug 4, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
[Transrectal prostatosonography. Follow-up in prostate cancer therapy]
Zeitschrift Fur Urologie Und Nephrologie
|September 1, 1985
Summary
Orchiectomy and drug therapy significantly reduced prostate size by one-third within six months for prostate cancer patients. This prostate shrinkage was most rapid in the initial two months of treatment.
Area of Science:
- Oncology
- Urology
Context:
- Prostate carcinoma treatment often involves orchiectomy and drug therapy.
- Monitoring prostate size is crucial for assessing treatment efficacy.
Purpose:
- To evaluate the impact of orchiectomy and drug therapy on prostate size.
- To compare the effectiveness of transrectal ultrasonography (TPS) and digital palpation in assessing prostate changes.
Summary:
- Thirty-five prostate carcinoma cases showed an average one-third prostate reduction within six months post-orchiectomy and drug therapy.
- The most significant prostate shrinkage occurred within the first two months.
- Transrectal ultrasonography (TPS) demonstrated reliability in assessing treatment effects, though routine gross measurement may not require it.
Impact:
- Transrectal ultrasonography (TPS) provides objective and reliable data on medication effects on prostate carcinomas.
- Findings suggest TPS is valuable for detailed assessment of treatment response in prostate cancer.
